Diaceutics (DXRX) full year 2021 results presentation March 2022

Diaceutics Founder & CEO, Peter Keeling, and CFO, Nick Roberts, present full year results for the period ended 31 December 2021. Diaceutics who are a diagnostic commercialisation company for precision testing, have transitioned to a recurring revenue model, and progressed further in the period than anticipated at the beginning of the year. These results show revenue increased 10% to £13.9m. Gross profit increased 13.4% to £10.7m. With a gross margin of 77%. Adjusted EBITDA was £2.3m and profit before tax £0.5m. Net cash £19.7m. Going forward they are focused on expanding their service offering, partner network and data repository to serve the diagnostic commercialisation needs both within and outside of oncology. Peter Keeling, Founder & CEO 00:17 – Introduction 01:59 – Overview of Diaceutics 02:54 – Overview of the period 04:37 – A transformative year 07:17 – Strategic roadmap 08:18 – Customer needs 09:38 – DXRX Platform 10:16 – Our products 11:34 – Our data 12:24 – Why Diaceutics wins 13:41 – ESG Nick Roberts, CFO 14:47 – Financial KPIs 16:53 – Income statement 18:01 – Revenue and margin growth 20:19 – Cash position 22:38 – Transition of business Peter Keeling, Founder & CEO 23:33 – Why invest in Diaceutics 24:30 – Outlook Diaceutics PLC is a United Kingdom-based diagnostic commercialization company. The principal activity of the Company is data analytics and implementation services. The Company is engaged in research and development activities in drug development science, testing data and software platform development. The Company's implementation services include test standardization, test quality assessment, laboratory tech support and others. The Company has established a range of products and outsourced advisory services, which help its pharma clients to optimize and deliver their marketing and implementation strategies for companion diagnostics. The Company provides the pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network. DXRX is the diagnostic commercialization platform for precision medicine, integrating multiple pipelines of diagnostic testing data from a global network of laboratories.